Clinical trials: Nonalcoholic Fatty Liver
Non-alcoholic Steatohepatitis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
This study will evaluate the efficacy, safety, and pharmacokinetics of BFKB8488A compared to placebo in participants with non-alcoholic steatohepatitis (NASH).
- Trial name
- BANFF (NCT04171765)
- Testing
- BFKB8488A
- Where
- 53 sites in United States, Belgium and 3 more
- Volunteers
- 46 people
- Sponsor
- Genentech, Inc.
Non Alcoholic Steatohepatitis
A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis
This study is intended to find out whether treatment with rosiglitazone improves the state of the liver and related blood markers in patients with nonalcoholic steatohepatitis (NASH).
- Trial name
- FLIRT (NCT00492700)
- Testing
- rosiglitazone
- Where
- France
- Volunteers
- 63 people
- Sponsor
- Association pour la Recherche sur les Maladies Hépatiques Virales
Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis
A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH
This is a randomized, double-blind study of MSDC-0602K or placebo in subjects with pre-T2D or T2D and evidence of NAFLD/NASH.
- Conditions
- Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis, Nonalcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT03970031
- Testing
- MSDC-0602K
- Volunteers
- 1,800 people
- Sponsor
- Cirius Therapeutics, Inc.
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver
Ultrasound and Attenuation Imaging
Fatty liver disease affects almost a 3rd of the United Kingdom (UK) population. Currently, this is being investigated using a type of MRI scan that reports how fatty or not a person's liver is, with a liver fat score, but many…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis, Steatosis of Liver
- Trial name
- NCT06552377
- Testing
- Ultrasound Attenuation imaging measurement
- Where
- United Kingdom
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Hywel Dda Health Board
HIV Infections, Fatty Liver Disease
Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
In HIV-infected people with metabolic fatty liver disease and liver fibrosis of any degree, as measured by non-invasive testing, antiretroviral treatment that includes rilpivinire for 18 months results in a slowing of progression…
- Trial name
- MAFALDA-R (NCT05898841)
- Testing
- Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day, Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day, Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine.
- Where
- 4 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Fundacion SEIMC-GESIDA
Non-alcoholic Fatty Liver Disease, Obesity
A Pilot Study on Whey Protein Supplementation in Non Alcoholic Fatty Liver Disease
An increase in dietary protein intake has been shown to blunt the increase in intrahepatic fat induced by high fat feeding in healthy individuals.
- Trial name
- PROTOB (NCT00870077)
- Testing
- ProWHEY 94 CFM, SponserR
- Where
- Switzerland
- Volunteers
- 11 people
- Sponsor
- University of Lausanne
Non-alcoholic Fatty Liver Disease, Glycogen Hepatopathy
Prevalence of Metabolic Liver Diseases in Patients With Type 1 Diabetes Mellitus
Nonalcoholic fatty liver disease (NAFLD) has been extensively studied in the context of type 2 diabetes mellitus (T2D) due to its higher prevalence and its association with obesity and syndrome metabolic, a well-established risk…
- Conditions
- Non-alcoholic Fatty Liver Disease, Glycogen Hepatopathy, Type 1 Diabetes, Liver Diseases
- Trial name
- NCT05054712
- Where
- 2 sites in Spain
- Volunteers
- 250 people
- Sponsor
- Consorci Sanitari de l'Alt Penedès i Garraf
Non-Alcoholic Fatty Liver Disease
Super HEROES: Searching How the Extract Rebaudioside Occludes Excess Steatosis
In order to determine whether rebaudioside consumption can be used as a treatment for adolescents with Non-alcoholic Fatty Liver Disease (NAFLD) by demonstrating a decrease in alanine aminotransferase (ALT) levels participants…
- Trial name
- NCT03985020
- Testing
- Stevia Intervention, Water Intervention
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Los Angeles
Liver Disease
Molecular Investigation of Non Alcoholic Fatty Liver Diseases in Obese Patients
Non alcoholic fatty liver diseases (NAFLD) are represented by two main pathological conditions, hepatic steatosis (HS) and non alcoholic steatohepatitis (NASH), which are characterized by the accumulation of fat in the liver.
- Trial name
- NCT00844779
- Testing
- Bariatric surgery, cholecystectomy or benign liver tumor removal
- Where
- 2 sites in France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Strasbourg, France
Morbid Obesity, Diabetes
Bariatric Surgery and Fatty Liver Disease
The study is based on data from morbidly obese patients who fulfilled the criteria for bariatric surgery during 2016-2018 at the Department of Surgery, University Hospital Ostrava, Czech Republic.
- Conditions
- Morbid Obesity, Diabetes, Hypertension
- Trial name
- NCT04569396
- Testing
- Biochemistry analysis, NAFLD fibrosis score, BMI measurement
- Where
- Czechia
- Volunteers
- 72 people
- Sponsor
- University Hospital Ostrava
Nonalcoholic Steatohepatitis
Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)
The overall purpose of this study is to examine the safety, tolerability, pharmacokinetics (how the body processes a drug), and activity of GS-9450 in preventing liver damage due to scarring, or fibrosis, caused by Non-Alcoholic…
- Trial name
- NCT00740610
- Testing
- GS-9450
- Where
- 33 sites in United States, France
- Volunteers
- 124 people
- Sponsor
- Gilead Sciences
Non-Alcoholic Steatohepatitis
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children
The purpose of this study is to document how often specific genotypes known to be associated with adult-onset NASH (Non-Alcoholic Steatohepatitis) occur in a pediatric cohort and investigate whether these genotypes are associated…
- Trial name
- NASH (NCT00677183)
- Where
- United States
- Sponsor
- Medical College of Wisconsin
NAFLD, Pre-diabetes
Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis
Oxidative stress is produced by imbalance between reactive oxygen species and antioxidant systems. This state is frequently associated with chronic diseases like obesity, insulin resistance, metabolic syndrome and hepatic…
- Trial name
- NCT02051842
- Testing
- Metadoxine
- Where
- Mexico
- Volunteers
- 100 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Fatty Liver
Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)
Multicenter, randomized, double-blinded, placebo-controlled clinical trial is focused on novel treatments for non-alcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Fatty Liver, Non-Alcoholic Steatohepatitis
- Trial name
- PUVENAFLD (NCT04198805)
- Testing
- Vitamin E [(all-rac)-α-tocopheryl acetate], Omega-3 fatty acid (DHA EE), Omega-3 fatty acid (DHA EE) & Vitamin E [(all-rac)-α-tocopheryl acetate]
- Where
- 15 sites in United States
- Volunteers
- 205 people
- Sponsor
- Naga P. Chalasani
Non-alcoholic Fatty Liver Disease
Plasma Betatrophin Levels in Non-alcoholic Fatty Liver Disease
The study searched for answers to two questions: 1-What are the plasma betatrophin levels in subjects with non-alcoholic fatty liver disease and healthy controls. 2.
- Trial name
- NCT02176811
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Gulhane School of Medicine
NASH
To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects
First-in-human, single centre, two parts, dose-escalation, parallel-group, safety, tolerability, pharmacokinetic and pharmacodynamic Phase I study.
- Trial name
- NCT06705998
- Testing
- BAR502 single dose, BAR502 multiple doses
- Where
- Switzerland
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- BAR Pharmaceuticals s.r.l.
Nonalcoholic Steatohepatitis
Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce associated complications in adults with cirrhosis due to NASH.
- Trial name
- STELLAR-4 (NCT03053063)
- Testing
- SEL
- Where
- 283 sites in United States, Australia and 20 more
- Volunteers
- 883 people
- Sponsor
- Gilead Sciences
Nonalcoholic Steatohepatitis
Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis
The purpose of the study is to see if the drug colesevelam is a potential treatment for Nonalcoholic Steatohepatitis(NASH).
- Trial name
- NCT01066364
- Testing
- Colesevelam Hcl
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of California, San Diego
Type 2 Diabetes, Coronary Heart Disease
NMR Metabolomics-Based Risk Assessment and Stratified Digital Health Interventions in Middle-Aged Adults (PREMAP)
PREMAP invites residents of the Eloisa region (South Savo, Finland) turning 45, 50, or 55 years of age in 2026 to undergo a blood-based NMR metabolomics risk assessment for five interlinked cardio-renal-metabolic conditions (type…
- Conditions
- Type 2 Diabetes, Coronary Heart Disease, Myocardial Infarction, Cerebrovascular Disease
- Trial name
- PREMAP (NCT07820800)
- Testing
- Digital health interventions
- Where
- Finland
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- University of Eastern Finland
Metabolic Dysfunction-associated Steatohepatitis
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in…
- Trial name
- NCT07288138
- Testing
- ECC4703, ECC0509
- Where
- 68 sites in United States
- Volunteers
- 160 people
- Sponsor
- Eccogene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.